Search tips
Search criteria 


Logo of bmjcredBMJ helping doctors make better decisionsSearchLatest content
Br Med J (Clin Res Ed). Apr 10, 1982; 284(6322): 1081–1084.
PMCID: PMC1497956
Survival and desferrioxamine in thalassaemia major.
B Modell, E A Letsky, D M Flynn, R Peto, and D J Weatherall
A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1002K), or click on a page image below to browse page by page.
Articles from British Medical Journal (Clinical Research Ed.) are provided here courtesy of
BMJ Publishing Group